Welcome to our dedicated page for Sanara Medtech news (Ticker: SMTI), a resource for investors and traders seeking the latest updates and insights on Sanara Medtech stock.
Sanara MedTech Inc. develops and commercializes medical technologies for the surgical market, including soft tissue repair, wound irrigation and bone fusion products used in operating rooms and sterile environments. Company news commonly covers financial results and guidance, sales and distribution activity, contracts for BIASURGE Advanced Surgical Solution, clinical and economic evidence for CellerateRX Surgical Powder, and product portfolio initiatives such as OsStic.
Coverage also includes conference presentations and business realignment disclosures, including the treatment of Tissue Health Plus as discontinued operations in Sanara's financial statements.
Sanara MedTech (Nasdaq: SMTI) reported first quarter 2026 net revenue of $27.8 million, up 19% year-over-year, with gross margin of 93% and operating income of $2.6 million.
Net income from continuing operations was $0.4 million ($0.04 per diluted share), and Adjusted EBITDA was $4.3 million. Soft tissue repair products drove 21% sales growth, while bone fusion products declined 2%. Cash was $13.6 million with $46.2 million long-term debt at March 31, 2026.
Sanara guided second quarter 2026 net revenue to $28.5–$29.5 million (10–14% growth) and reaffirmed full-year 2026 net revenue guidance of $116–$121 million (13–17% growth).
Sanara MedTech (Nasdaq: SMTI) will report first quarter 2026 financial results on May 12, 2026 before U.S. markets open and will host a conference call and webcast at 8:00 a.m. ET.
The call will cover the quarter ended March 31, 2026, include a Q&A, offer telephonic and online replays, and the webcast will be available via the company investor relations site.
Sanara MedTech (Nasdaq: SMTI) reported fourth-quarter and full-year 2025 results and reaffirmed 2026 guidance. Full-year net revenue rose 19% to $103.1M, Adjusted EBITDA was $17.0M, and the company reaffirmed 2026 revenue guidance of $116M–$121M (≈13%–17% growth).
Management highlighted commercial expansion, Vizient Innovative Technology contracting for BIASURGE, planned U.S. launch of OsStic in 1Q2027 pending FDA clearance, and increased R&D investment.
Sanara MedTech (Nasdaq: SMTI) announced publication of a peer-reviewed Journal of Medical Economics study (March 11, 2026) evaluating CellerateRX Surgical Powder for high-risk spine surgery wounds. The one-year economic model (2025 USD) found $3,852 cost savings, a 0.007 QALY gain, and a $4,542 net monetary benefit per patient; readmissions and revisions accounted for $2,238 and $835 of savings. Probabilistic analysis showed dominance in >99% of simulations.
Sanara MedTech (Nasdaq: SMTI) will report its fourth quarter and full year 2025 financial results on March 24, 2026 before U.S. markets open. The company will host a conference call and webcast on March 24, 2026 at 8:00 a.m. ET to discuss results for the quarter and year ended December 31, 2025 and answer questions.
Dial-in details, replay instructions, and a live webcast link are provided; an online replay will be available for approximately one year.
Sanara MedTech (Nasdaq: SMTI) will present at the TD Cowen 46th Annual Health Care Conference in Boston. Management is scheduled to deliver a presentation on Tuesday, March 3, 2026 at approximately 9:10 a.m. ET.
Presentation materials and a live audio webcast will be posted to the company’s Investor Relations website prior to the presentation, and an archived replay will be available after the conference.
Sanara MedTech (Nasdaq: SMTI) reported unaudited preliminary results for Q4 and full-year 2025 and issued full-year 2026 guidance. Q4 2025 revenue is expected to be $27.2M–$27.7M (up ~3%–5%; or +11%–13% ex-$1.8M BIASURGE 2024 sales). FY 2025 revenue is expected at $102.7M–$103.2M (≈19% growth; ≈21%–22% ex the $1.8M item). Cash was ≈$16.6M and long-term debt ≈$46.0M at 12/31/2025. Operational highlights include a Vizient Innovative Technology contract for BIASURGE and continued work with Biomimetic Innovations on OsStic, targeted for U.S. commercial introduction in Q1 2027 pending FDA clearance. 2026 revenue guidance is $116M–$121M (+13%–17% vs 2025 midpoint). The results remain unaudited and subject to final audit adjustments.
Sanara MedTech (Nasdaq: SMTI) announced that its BIASURGE® Advanced Surgical Solution received an Innovative Technology contract from Vizient, effective January 1, 2026. The contract followed recommendation by Vizient client-led hospital councils and provides Vizient members access to BIASURGE at pre-negotiated pricing and contracted terms. Vizient represents a broad client base with a portfolio exceeding $156 billion in annual purchasing volume. The company highlighted BIASURGE’s no-rinse irrigation and antimicrobial preservative as clinical differentiators and said it will engage Vizient clients to introduce the product and educate on surgical wound treatment potential.
Sanara MedTech (Nasdaq: SMTI) and Biomimetic Innovations provided a progress update on OsStic™, a synthetic injectable structural bio-adhesive targeted for U.S. commercial launch in Q1 2027, conditional on anticipated FDA clearance. OsStic received FDA Breakthrough Device Designation (Dec 2023) and a U.S. patent was granted in 2025 (U.S. Patent No. 12,251,490) covering compositions, adhesives, kits, and prefilled syringes. The release cites preclinical mechanical testing showing 40x stronger bonding versus traditional calcium phosphate bone cement and notes ongoing product development, clinical, regulatory, and medical education milestones in 2025.
Sanara MedTech (Nasdaq: SMTI) said company management will present at the Piper Sandler 37th Annual Healthcare Conference in New York, running December 2–4, 2025. Management will deliver a presentation to investors on Wednesday, December 3 at ~9:30 a.m. Eastern Time. Presentation materials will be posted to the company’s investor relations website prior to the talk. A live audio webcast will be accessible under the Events section of the investor relations site, and an archive will be available for replay after the conference.